Table 4.
Compounds | Cell Lines (IC50, µM); Values Are Expressed as Mean ± S.D. (n = 3). | ||||||
---|---|---|---|---|---|---|---|
MOLT-3 | HepG-2 | A549 | HuCCA-1 | HeLa | MDA-MB-231 | MRC-5 | |
1 | 17.86 ± 0.26 | 12.71 ± 1.67 | 20.04 ± 1.52 | 21.32 ± 1.84 | ND | ND | 40.13 ± 1.23 |
2 | 32.36 ± 1.08 | 44.78 ± 3.79 | 38.59 ± 0.24 | 37.92 ± 3.01 | ND | ND | 60.61 ± 12.75 |
3 | 8 (27.17) a | 44.61 ± 9.76 | 9 (54.35) a | 47.48 ± 6.96 | ND | ND | 24.70 (54.35) a |
4 | 0 (12.35) a | 20.32 (24.70) a | 2 (12.35) a | 0 (12.35) a | ND | ND | 5.45 (24.70) a |
6 | 20.07 ± 0.52 | 54.89 ± 2.04 | 34.73 ± 17.71 | 37.06 ± 0.36 | ND | ND | 63.36 ± 8.30 |
7 | 16.33 ± 18.02 | 26.46 ± 5.32 | 23.58 ± 2.00 | 25.07 ± 2.27 | 11.23 ± 0.05 | 27.03 ± 7.79 | ND |
8 | 43 (108.70) a | 18.23 ± 1.86 | 32.62 ± 3.64 | 103.35 ± 2.29 | ND | ND | 90.11 ± 6.88 |
10 | 2 (29.34) a | 49.75 ± 3.96 | 52.15 ± 3.35 | 44 (58.69) a | ND | ND | 44.77 ± 1.36 |
12 | 36.57 ± 1.11 | 56.50 ± 2.15 | 54.26 ± 3.84 | 66.11 ± 0.90 | ND | ND | 76.94 ± 10.65 |
13 | 14.90 ± 0.25 | 12.53 ± 0.84 | 17.91 ± 2.26 | 20.79 ± 2.32 | ND | ND | 37.68 ± 10.65 |
14 | 24.45 ± 3.11 | 41.41 ± 3.24 | 23.76 ± 1.87 | 34.41 ± 1.83 | ND | ND | 65.90 ± 4.54 |
15 | 12.84 ± 0.98 | 7.10 ± 4.76 | 37.93 ± 0.07 | 37.58 ± 1.40 | 6.11 ± 0.02 | 18.01 ± 5.74 | ND |
16 | 14.58 ± 0.36 | 11.31 ± 9.29 | 29.11 ± 8.25 | 34.60 ± 3.85 | ND | ND | 49.60 ± 6.67 |
Doxorubicin b | ND | 0.55 ± 0.12 | 0.92 ± 0.06 | 2.24 ± 0.15 | 0.17 ± 0.10 | 1.78 ± 0.54 | 24.85 (50.00) a |
Etoposide b | 0.07 ± 0.005 | 31.50 ± 15.56 | ND | ND | ND | ND | ND |
a % inhibition (at concentration, μM); b positive control; ND: not determined.